News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,383 Results
Type
Article (39560)
Company Profile (247)
Press Release (656576)
Section
Business (204106)
Career Advice (2007)
Deals (35412)
Drug Delivery (94)
Drug Development (81013)
Employer Resources (172)
FDA (16157)
Job Trends (14844)
News (345053)
Policy (32500)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2547)
Accelerated approval (4)
Adcomms (20)
Allergies (80)
Alliances (49377)
ALS (83)
Alzheimer's disease (1357)
Antibody-drug conjugate (ADC) (109)
Approvals (16159)
Artificial intelligence (233)
Autoimmune disease (16)
Automation (14)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (101)
Biotechnology (175)
Bladder cancer (58)
Brain cancer (25)
Breast cancer (252)
Cancer (2016)
Cardiovascular disease (162)
Career advice (1674)
Career pathing (29)
CAR-T (140)
Cell therapy (397)
Cervical cancer (19)
Clinical research (65742)
Collaboration (769)
Compensation (466)
Complete response letters (19)
COVID-19 (2582)
CRISPR (35)
C-suite (211)
Cystic fibrosis (98)
Data (1986)
Decentralized trials (2)
Denatured (16)
Depression (38)
Diabetes (249)
Diagnostics (6337)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (113)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (85)
Earnings (86223)
Editorial (32)
Employer branding (21)
Employer resources (146)
Events (111716)
Executive appointments (649)
FDA (17279)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (691)
Gene editing (97)
Generative AI (18)
Gene therapy (278)
GLP-1 (685)
Government (4383)
Grass and pollen (4)
Guidances (49)
Healthcare (18810)
Huntington's disease (22)
IgA nephropathy (24)
Immunology and inflammation (103)
Indications (26)
Infectious disease (2714)
Inflammatory bowel disease (132)
Inflation Reduction Act (8)
Influenza (48)
Intellectual property (87)
Interviews (311)
IPO (16486)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (34)
Layoffs (455)
Leadership (16)
Legal (7901)
Liver cancer (70)
Lung cancer (293)
Lymphoma (134)
Machine learning (4)
Management (58)
Manufacturing (268)
MASH (61)
Medical device (13326)
Medtech (13331)
Mergers & acquisitions (19407)
Metabolic disorders (632)
Multiple sclerosis (72)
NASH (16)
Neurodegenerative disease (80)
Neuropsychiatric disorders (24)
Neuroscience (1841)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2458)
Now hiring (37)
Obesity (340)
Opinion (202)
Ovarian cancer (72)
Pain (78)
Pancreatic cancer (76)
Parkinson's disease (138)
Partnered (20)
Patents (204)
Patient recruitment (97)
Peanut (46)
People (57104)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20473)
Phase II (28949)
Phase III (21580)
Pipeline (1057)
Podcasts (45)
Policy (114)
Postmarket research (2563)
Preclinical (8658)
Press Release (64)
Prostate cancer (94)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (359)
Real estate (5901)
Recruiting (65)
Regulatory (22154)
Reports (46)
Research institute (2318)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (39)
Schizophrenia (64)
Series A (121)
Series B (78)
Service/supplier (11)
Sickle cell disease (51)
Southern California (2118)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3571)
State (2)
Stomach cancer (13)
Supply chain (60)
Tariffs (11)
The Weekly (27)
United States (21328)
Vaccines (657)
Venture capitalists (37)
Webinars (12)
Weight loss (224)
Women's health (33)
Worklife (15)
Date
Last 7 days (653)
Last 30 days (2450)
Last 365 days (33269)
2025 (8275)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29266)
2010 (27328)
Location
Africa (719)
Alabama (49)
Alaska (7)
Arizona (224)
Arkansas (13)
Asia (37715)
Australia (6168)
California (5582)
Canada (1880)
China (476)
Colorado (247)
Connecticut (256)
Delaware (128)
Europe (80872)
Florida (828)
Georgia (196)
Idaho (57)
Illinois (500)
India (24)
Indiana (292)
Iowa (9)
Japan (143)
Kansas (101)
Kentucky (23)
Louisiana (9)
Maine (61)
Maryland (834)
Massachusetts (4195)
Michigan (209)
Minnesota (371)
Mississippi (2)
Missouri (77)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1592)
New Mexico (28)
New York (1603)
North Carolina (922)
North Dakota (7)
Northern California (2458)
Ohio (192)
Oklahoma (14)
Oregon (33)
Pennsylvania (1264)
Puerto Rico (9)
Rhode Island (27)
South America (1095)
South Carolina (18)
South Dakota (1)
Southern California (2118)
Tennessee (95)
Texas (832)
Utah (164)
Virginia (130)
Washington D.C. (57)
Washington State (516)
West Virginia (3)
Wisconsin (49)
696,383 Results for "medicinova inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
MediciNova, Inc. announces that its Chief Business Officer, David H. Crean, Ph.D., will assume management of the Company’s investor engagement, corporate communications, and public relations activities.
June 20, 2024
·
5 min read
Biotech Beach
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis of eye cancer.
May 20, 2024
·
6 min read
Biotech Beach
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange, announced that MediciNova conducted two poster presentations at the 92nd European Atherosclerosis Society 2024 Congress held online May 26-29, 2024.
May 28, 2024
·
9 min read
Biotech Beach
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166.
May 7, 2024
·
4 min read
Drug Development
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
MediciNova, Inc. announced that MediciNova’s collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 in Glioblastoma at the American Society of Clinical Oncology Annual meeting 2024 held May 31- June 4th in Chicago, IL.
June 3, 2024
·
7 min read
Policy
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.
June 5, 2024
·
5 min read
Press Releases
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
November 20, 2024
·
8 min read
Biotech Beach
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of chlorine-induced acute respiratory distress syndrome.
May 14, 2024
·
5 min read
Biotech Beach
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
MediciNova, Inc. today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
March 26, 2024
·
5 min read
Biotech Beach
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
MediciNova, Inc. announced that MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 in a CIALI model at the SOT 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah.
March 12, 2024
·
7 min read
1 of 69,639
Next